Gary F Baxter

List of Publications by Year
in descending order

64 papers	5,643 citations	109321 35 h-index	123424 61 g-index
66 all docs	66 docs citations	66 times ranked	5432 citing authors

#	Article	IF	Citations
1	Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning. Pharmacological Reviews, 2007, 59, 418-458.	16.0	631
2	Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning. Pharmacological Reviews, 2014, 66, 1142-1174.	16.0	521
3	Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovascular Research, 2002, 55, 534-543.	3.8	487
4	Postconditioning and protection from reperfusion injury: where do we stand? * Position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research, 2010, 87, 406-423.	3.8	447
5	Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemiaâ€“reperfusion injury. Basic Research in Cardiology, 2006, 101, 53-60.	5.9	247
6	Autocrine and paracrine actions of natriuretic peptides in the heart. , 2004, 101, 113-129.		188
7	B-type natriuretic peptide limits infarct size in rat isolated hearts via K_{ATP}channel opening. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1592-H1600.	3.2	161
8	Regulation of cardiovascular cell function by hydrogen sulfide (H₂S). Cell Biochemistry and Function, 2010, 28, 95-106.	2.9	132
9	Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide. Circulation, 2001, 103, 3111-3116.	1.6	128
10	The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on. Basic Research in Cardiology, 2002, 97, 268-275.	5.9	108
11	Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2598-H2606.	3.2	103
12	Reperfusion Injury Revisited Is There a Role for Growth Factor Signaling in Limiting Lethal Reperfusion Injury?. Trends in Cardiovascular Medicine, 1999, 9, 245-249.	4.9	99
13	Cardioprotective Effects of Transforming Growth Factor-Î²1 During Early Reoxygenation or Reperfusion Are Mediated by p42/p44 MAPK. Journal of Cardiovascular Pharmacology, 2001, 38, 930-939.	1.9	98
14	The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Research in Cardiology, 2000, 95, 472-478.	5.9	96
15	Myocardial Protection Afforded by Nicorandil and Ischaemic Preconditioning in a Rabbit Infarct Model In Vivo. Journal of Cardiovascular Pharmacology, 1998, 31, 74-79.	1.9	95
16	The natriuretic peptides. Basic Research in Cardiology, 2004, 99, 71-75.	5.9	93
17	Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning. Basic Research in Cardiology, 2000, 95, 1-10.	5.9	92
18	Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. Journal of Molecular and Cellular Cardiology, 2003, 35, 1063-1071.	1.9	88

#	Article	IF	Citations
19	Prolonging the Delayed Phase of Myocardial Protection: Repetitive Adenosine A1Receptor Activation Maintains Rabbit Myocardium in a Preconditioned State 11Dr. Dana is supported by a Junior Research Fellowship, and Dr. Baxter by an Intermediate Fellowship, from the British Heart Foundation, London. Continuing support (Drs. Dana and Baxter) is provided by the Hatter Foundation, London.. Journal of the American College of Cardiology, 1998, 31, 1142-1149.	2.8	85
20	Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Research in Cardiology, 2010, 105, 643-650.	5.9	83
21	Genistein, a Tyrosine Kinase Inhibitor, Blocks the â€œSecond Window of Protectionâ€•48 h after Ischemic Preconditioning in the Rabbit. Journal of Molecular and Cellular Cardiology, 1997, 29, 1885-1893.	1.9	78
22	B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Research in Cardiology, 2007, 102, 529-541.	5.9	77
23	Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regulatory Peptides, 2008, 146, 271-277.	1.9	76
24	Ischemic preconditioning is lost in aging hypertensive rat heart: Independent effects of aging and longstanding hypertension. Experimental Gerontology, 2007, 42, 807-814.	2.8	71
25	AP39, a mitochondria-targeting hydrogen sulfide (H₂S) donor, protects against myocardial reperfusion injury independently of salvage kinase signalling. British Journal of Pharmacology, 2017, 174, 287-301.	5.4	69
26	Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Failure Reviews, 2007, 12, 279-291.	3.9	67
27	Natriuretic peptides and myocardial ischaemia. Basic Research in Cardiology, 2004, 99, 90-93.	5.9	61
28	Nitric oxide treatments as adjuncts to reperfusion in acute myocardial infarction: a systematic review of experimental and clinical studies. Basic Research in Cardiology, 2016, 111, 23.	5.9	58
29	Pharmacological postconditioning against myocardial infarction with a slow-releasing hydrogen sulfide donor, GYY4137. Pharmacological Research, 2016, 111, 442-451.	7.1	54
30	Role of nuclear factor-Îº B activation in acute ischaemia-reperfusion injury in myocardium. British Journal of Pharmacology, 2003, 138, 894-900.	5.4	49
31	Limitation of Myocardial Reperfusion Injury by AMP579, an Adenosine A1/A2AReceptor Agonist: Role of A2AReceptor and Erk1/2. Cardiovascular Drugs and Therapy, 2003, 17, 415-425.	2.6	48
32	Protein Kinase C is Involved in Resistance to Myocardial Infarction Induced by Heat Stress. Journal of Molecular and Cellular Cardiology, 1997, 29, 3311-3319.	1.9	46
33	Myocardial ischemic tolerance following heat stress is abolished by ATP-sensitive potassium channel blockade. Cardiovascular Drugs and Therapy, 1997, 11, 679-686.	2.6	46
34	Pre- and postconditioning the heart with hydrogen sulfide (H2S) against ischemia/reperfusion injury in vivo: a systematic review and meta-analysis. Basic Research in Cardiology, 2018, 113, 6.	5.9	44
35	Adrenomedullin: regulator of systemic and cardiac homeostasis in acute myocardial infarction. , 2005, 105, 95-112.		40
36	Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. Journal of the American College of Cardiology, 2001, 37, 1996-2001.	2.8	39

#	Article	IF	Citations
37	Protection of the myocardium by ischaemic preconditioning: Mechanisms and therapeutic implications. , 1996, 69, 143-151.		34
38	L-Cysteine Stimulates Hydrogen Sulfide Synthesis in Myocardium Associated With Attenuation of Ischemia-Reperfusion Injury. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 53-59.	2.0	34
39	NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovascular Research, 2014, 101, 220-228.	3.8	34
40	Pharmacological targets revealed by myocardial postconditioning. Current Opinion in Pharmacology, 2009, 9, 177-188.	3.5	33
41	Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy. Pharmacological Research, 2007, 55, 42-48.	7.1	31
42	Ischaemic Preconditioning of Myocardium. Annals of Medicine, 1997, 29, 345-352.	3.8	29
43	A critical cytoprotective role of endogenous adrenomedullin in acute myocardial infarction. Journal of Molecular and Cellular Cardiology, 2006, 41, 360-363.	1.9	29
44	Bradykinin elicits â€œsecond windowâ€•myocardial protection in rat heart through an NO-dependent mechanism. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H1458-H1464.	3.2	28
45	Nitric oxide/cGMP signalling mediates the cardioprotective action of adrenomedullin in reperfused myocardium. Basic Research in Cardiology, 2010, 105, 257-266.	5.9	28
46	Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling. Free Radical Biology and Medicine, 2021, 166, 33-52.	2.9	28
47	Effect of radiofrequency catheter ablation on the biochemical marker ischemia modified albumin. American Journal of Cardiology, 2004, 94, 234-236.	1.6	26
48	Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovascular Drugs and Therapy, 1999, 13, 115-122.	2.6	22
49	Delayed or Second Window Preconditioning Induced by Adenosine A1 Receptor Activation Is Independent of Early Generation of Nitric Oxide or Late Induction of Inducible Nitric Oxide Synthase. Journal of Cardiovascular Pharmacology, 2001, 38, 278-287.	1.9	20
50	Postconditioning signalling in the heart: mechanisms and translatability. British Journal of Pharmacology, 2015, 172, 1933-1946.	5.4	19
51	Novel Approaches and Opportunities for Cardioprotective Signaling Through 3â€²,5â€²-Cyclic Guanosine Monophosphate Manipulation. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 269-282.	2.0	18
52	Natriuretic peptides modulate ATP-sensitive K+ channels in rat ventricular cardiomyocytes. Basic Research in Cardiology, 2014, 109, 402.	5.9	18
53	Cardioprotective effects of Viscum album L. subsp. album (European misletoe) leaf extracts in myocardial ischemia and reperfusion. Journal of Ethnopharmacology, 2017, 209, 203-209.	4.1	17
54	Reduction of infarct size in isolated rat heart by CsA and FK506: possible role of phosphatase inhibition. Cardiovascular Drugs and Therapy, 1998, 12, 499-501.	2.6	14

#	Article	IF	Citations
55	Protection against global ischemia in the rabbit isolated heart 24 hours after transient adenosine A1 receptor activation. Cardiovascular Drugs and Therapy, 1997, 11, 83-85.	2.6	13
56	Acute Actions of Natriuretic Peptides in Coronary Vasculature and Ischaemic Myocardium. Current Pharmaceutical Design, 2004, 10, 2477-2482.	1.9	11
57	Homologous and heterologous desensitization of guanylyl cyclase-B signaling in GH3 somatolactotropes. Cell and Tissue Research, 2014, 355, 425-436.	2.9	5
58	Natriuretic peptide activation of extracellular regulated kinase 1/2 (ERK1/2) pathway by particulate guanylyl cyclases in GH3 somatolactotropes. Cell and Tissue Research, 2017, 369, 567-578.	2.9	4
59	Evidence for serca and BKCa activation in BNP protection of reperfused myocardium. Journal of Molecular and Cellular Cardiology, 2008, 44, 717.	1.9	3
60	B-type natriuretic peptide limits reperfusion injury via opening of ATP-sensitive potassium channels. Journal of Molecular and Cellular Cardiology, 2006, 40, 967-968.	1.9	1
61	Activation of particulate guanylate cyclase during early reperfusion limits infarct size in the rat isolated heart. Journal of Molecular and Cellular Cardiology, 2007, 42, S209.	1.9	1
62	Natriuretic peptides in animal models of cardiovascular disease. Cardiovascular Endocrinology, 2014, 3, 19-26.	0.8	1
63	Activation of the h2s-generating enzyme, cystathionine-Î³-lyase, protects against myocardial ischaemiaâ€"reperfusion injury. Journal of Molecular and Cellular Cardiology, 2006, 40, 960.	1.9	0
64	Targeting of soluble guanylyl cyclase limits infarct size in a model of acute myocardial infarction. BMC Pharmacology, 2011, 11, .	0.4	0